Finland uses only 48 percent of new cancer medicines, Ilta-Sanomat reports. In Germany, the corresponding figure is 91 percent, highlighting a striking difference between the two countries.

The figures raise a broader question about why the adoption of new medicines appears to move more slowly in Finland than in Germany. Experts are now examining the reasons for the gap and considering what could be changed in Finnish practice.